Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)

SHA:688266 Cash Flow Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-137.83	-278.58	-457.33	-451
Depreciation & Amortization	55.26	54.04	66.37	50.77
Other Amortization	6.07	6.36	4.44	2.62
Loss (Gain) From Sale of Assets	-	-	-0.02	-
Asset Writedown & Restructuring Costs	-	0.28	0.11	0.01
Loss (Gain) From Sale of Investments	-6.86	-14.68	-6.58	-12.8
Provision & Write-off of Bad Debts	2.22	0.64	1.4	3.28
Other Operating Activities	-33.48	8.77	-15.57	-4.53
Change in Accounts Receivable	-58.17	-38.35	-17.41	-84.19
Change in Inventory	-72.01	-11.87	-47.07	-28.77
Change in Accounts Payable	285.27	78.49	67.14	38.99
Change in Other Net Operating Assets	1.62	-34.11	37.07	34.62
Operating Cash Flow	38.2	-232.75	-370.34	-454.62
Capital Expenditures	-95.69	-62.6	-88.62	-70.74
Sale of Property, Plant & Equipment	-	0	0	0
Investment in Securities	-1,764	115	-182.1	380.01
Other Investing Activities	14.86	12.44	6.66	17.39
Investing Cash Flow	-1,845	64.84	-264.06	326.66
Long-Term Debt Issued	1,288	983.8	561	171.4
Long-Term Debt Repaid	-1,150	-644.19	-242.77	-64.91
Net Debt Issued (Repaid)	138.43	339.61	318.23	106.49
Issuance of Common Stock	0.34	1,192	-	-
Common Dividends Paid	-24.56	-21.17	-11.22	-4.14
Other Financing Activities	-165.52	-1.45	-24.23	-8.36
Financing Cash Flow	-51.32	1,509	282.79	93.99
Foreign Exchange Rate Adjustments	-2.3	0.22	4.07	-1.44
Net Cash Flow	-1,861	1,342	-347.54	-35.41
Free Cash Flow	-57.49	-295.35	-458.97	-525.36
Free Cash Flow Margin	-10.79%	-76.43%	-151.82%	-275.98%
Free Cash Flow Per Share	-0.22	-1.16	-1.92	-2.19
Cash Income Tax Paid	51.24	15.67	-17.55	-30.33
Levered Free Cash Flow	-165.35	-325.09	-297.1	-353.47
Unlevered Free Cash Flow	-147.3	-310.99	-289.58	-350.71
Change in Working Capital	152.83	-9.58	36.84	-42.98

Source: S&P Global Market Intelligence. Standard template. Financial Sources.